DE60141409D1 - Homologe des nogo rezeptors - Google Patents

Homologe des nogo rezeptors

Info

Publication number
DE60141409D1
DE60141409D1 DE60141409T DE60141409T DE60141409D1 DE 60141409 D1 DE60141409 D1 DE 60141409D1 DE 60141409 T DE60141409 T DE 60141409T DE 60141409 T DE60141409 T DE 60141409T DE 60141409 D1 DE60141409 D1 DE 60141409D1
Authority
DE
Germany
Prior art keywords
proteins
nogo
methods
compositions
specifically
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60141409T
Other languages
German (de)
English (en)
Inventor
Stephen M Strittmatter
Richard L Cate
Dinah W Sah
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Biogen Inc
Biogen MA Inc
Original Assignee
Yale University
Biogen Idec Inc
Biogen Idec MA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University, Biogen Idec Inc, Biogen Idec MA Inc filed Critical Yale University
Application granted granted Critical
Publication of DE60141409D1 publication Critical patent/DE60141409D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
DE60141409T 2000-10-06 2001-10-06 Homologe des nogo rezeptors Expired - Lifetime DE60141409D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23836100P 2000-10-06 2000-10-06
PCT/US2001/031488 WO2002029059A2 (en) 2000-10-06 2001-10-06 Nogo receptor homologs

Publications (1)

Publication Number Publication Date
DE60141409D1 true DE60141409D1 (de) 2010-04-08

Family

ID=22897532

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60141409T Expired - Lifetime DE60141409D1 (de) 2000-10-06 2001-10-06 Homologe des nogo rezeptors

Country Status (12)

Country Link
US (5) US20030124704A1 (cg-RX-API-DMAC7.html)
EP (1) EP1325130B1 (cg-RX-API-DMAC7.html)
JP (2) JP4465148B2 (cg-RX-API-DMAC7.html)
AT (1) ATE458815T1 (cg-RX-API-DMAC7.html)
AU (2) AU1153902A (cg-RX-API-DMAC7.html)
CA (1) CA2424834A1 (cg-RX-API-DMAC7.html)
DE (1) DE60141409D1 (cg-RX-API-DMAC7.html)
DK (1) DK1325130T3 (cg-RX-API-DMAC7.html)
ES (1) ES2341608T3 (cg-RX-API-DMAC7.html)
NZ (1) NZ525422A (cg-RX-API-DMAC7.html)
PT (1) PT1325130E (cg-RX-API-DMAC7.html)
WO (1) WO2002029059A2 (cg-RX-API-DMAC7.html)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7119165B2 (en) * 2000-01-12 2006-10-10 Yale University Nogo receptor-mediated blockade of axonal growth
PT1325130E (pt) * 2000-10-06 2010-05-31 Biogen Idec Inc Homólogos do receptor de nogo
US20040259092A1 (en) * 2001-08-27 2004-12-23 Carmen Barske Nogo receptor homologues and their use
JP2005519584A (ja) * 2001-10-22 2005-07-07 ノバルティス アクチエンゲゼルシャフト Ｎｏｇｏレセプターホモログおよびそれらの使用
US7309485B2 (en) * 2001-12-03 2007-12-18 Children's Medical Center Corporation Reducing myelin-mediated inhibition of axon regeneration
WO2004005510A1 (ja) * 2002-07-05 2004-01-15 Shionogi & Co., Ltd. 新規Nogo受容体様ポリペプチドおよびそのＤＮＡ
WO2004014311A2 (en) * 2002-08-10 2004-02-19 Yale University Nogo receptor antagonists
ES2537015T3 (es) 2003-03-19 2015-06-01 Biogen Ma Inc. Proteína de unión del receptor de NOGO
WO2004090103A2 (en) 2003-04-04 2004-10-21 University Of Rochester Identification of novel nogo-receptors and methods related thereto
MXPA05011100A (es) * 2003-04-16 2006-04-18 Univ Yale Antagonistas de receptor nogo para el tratamiento de condiciones que comprenden placas amiloideas.
US20080274112A1 (en) * 2003-08-07 2008-11-06 Lee Daniel H S Nogo Receptor Antagonists
CA2549000A1 (en) * 2003-12-16 2005-06-30 Children's Medical Center Corporation Method for treating neurological disorders
US8912144B2 (en) * 2003-12-16 2014-12-16 Children's Medical Center Corporation Method for treating stroke via administration of NEP1-40 and inosine
CN1946418A (zh) * 2004-01-30 2007-04-11 比奥根艾迪克Ma公司 利用nogo受体拮抗剂治疗涉及多巴胺能神经元退变的疾病
PL1776136T3 (pl) 2004-06-24 2013-03-29 Biogen Ma Inc Leczenie stanów związanych z demielinizacją
JP2008515804A (ja) * 2004-10-01 2008-05-15 イェール ユニバーシティ Ｎｏｇｏ−Ａポリペプチド断片、改変体Ｎｏｇｏレセプター１ポリペプチドおよびそれらの使用
EP1904091A4 (en) * 2005-07-07 2009-12-23 Univ Yale COMPOSITIONS AND METHODS FOR SUPPRESSING THE INHIBITION OF AXON GROWTH
ES2434470T3 (es) 2005-07-08 2013-12-16 Biogen Idec Ma Inc. Anticuerpos SP35 y usos de éstos
WO2007025219A2 (en) * 2005-08-25 2007-03-01 Biogen Idec Ma Inc. Nogo receptor polypeptides and polypeptide fragments and uses thereof
EP2526968A3 (en) 2006-01-27 2013-05-22 Biogen Idec MA Inc. Nogo receptor antagonists
US20110123535A1 (en) * 2006-05-15 2011-05-26 Biogen Idec Ma Inc. Use of Nogo Receptor-1 (NGR1) for Promoting Oligodendrocyte Survival
WO2007137303A2 (en) * 2006-05-24 2007-11-29 Myelin Repair Foundation, Inc. Permeability of blood-brain barrier
US20100047232A1 (en) * 2006-11-14 2010-02-25 Jasvinder Atwal Modulators of neuronal regeneration
CN101529255A (zh) * 2006-11-14 2009-09-09 健泰科生物技术公司 神经元再生的调控剂
WO2009009743A2 (en) * 2007-07-12 2009-01-15 Institute For Advance Study Sequence optimization for expression of a foreign gene
WO2009076359A2 (en) * 2007-12-11 2009-06-18 Genentech, Inc. Modulators of neuronal regeneration
US8992918B2 (en) 2008-03-13 2015-03-31 Yale University Reactivation of axon growth and recovery in chronic spinal cord injury
CL2009001155A1 (es) * 2008-05-13 2010-06-04 Genentech Inc Anticuerpo anti-pirb/lilrb aislado; polinucleotido que lo codifica; vector; celula huesped; metodo de obtencion; composicion farmaceutica que lo comprende; kit; y su uso para tratar enfermedades neurodegenerativas.
DK2982695T3 (da) 2008-07-09 2019-05-13 Biogen Ma Inc Sammensætninger, der omfatter antistoffer mod lingo eller fragmenter deraf
EP2392208B1 (en) * 2010-06-07 2016-05-04 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Fusion proteins comprising a DNA-binding domain of a Tal effector protein and a non-specific cleavage domain of a restriction nuclease and their use
US9120111B2 (en) 2012-02-24 2015-09-01 Rain Bird Corporation Arc adjustable rotary sprinkler having full-circle operation and automatic matched precipitation
EA030716B1 (ru) 2012-05-14 2018-09-28 Байоджен Ма Инк. Антагонисты lingo-2 для лечения заболеваний, в которых участвуют двигательные нейроны
US9156043B2 (en) 2012-07-13 2015-10-13 Rain Bird Corporation Arc adjustable rotary sprinkler with automatic matched precipitation
US10435467B2 (en) 2015-01-08 2019-10-08 Biogen Ma Inc. LINGO-1 antagonists and uses for treatment of demyelinating disorders
US12343748B2 (en) 2021-03-16 2025-07-01 Rain Bird Corporation Multi-mode rotor sprinkler apparatus and method
US12434252B2 (en) 2022-04-20 2025-10-07 Rain Bird Corporation Full-circle and part-circle rotor sprinkler
US12440855B2 (en) 2022-10-27 2025-10-14 Rain Bird Corporation Multi-mode rotor sprinkler apparatus and method

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5250414A (en) 1988-11-04 1993-10-05 Erziehungsdirektion Of The Canton Zurich Diagnostic methods using neurite growth regulatory factors
DE68923362T2 (de) 1988-11-04 1996-03-28 Zuerich Erziehungsdirektion Wachstumsregelfaktoren für neuriten.
CA1341050C (en) 1988-11-04 2000-07-11 Martin E. Schwab Neurite growth regulatory factors
JPH07509002A (ja) 1993-02-11 1995-10-05 エルツィーヒュングスディレクション　オブ　ザ　キャントン　チューリッヒ ニューロトロフィンとミエリン−関連の軸索成長阻害タンパク質に対する抗体との組み合わせが中枢神経系の再生を促進する
WO2000032221A2 (en) 1998-12-01 2000-06-08 Genentech, Inc. Promotion or inhibition of angiogenesis and cardiovascularization
WO2000073452A2 (en) 1999-06-02 2000-12-07 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US5858708A (en) 1996-08-12 1999-01-12 Bandman; Olga Polynucleotides encoding two novel human neuroendocrine-specific proteins
WO2000053756A2 (en) 1999-03-08 2000-09-14 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO1999007891A1 (en) * 1997-08-05 1999-02-18 Human Genome Sciences, Inc. 90 human secreted proteins
NZ507435A (en) 1998-03-10 2003-12-19 Genentech Inc Novel polypeptides and nucleic acids with homology to cornichon
AU4682999A (en) 1998-06-16 2000-01-05 Human Genome Sciences, Inc. 94 human secreted proteins
ATE483021T1 (de) 1998-07-22 2010-10-15 Smithkline Beecham Ltd Protein, das mit einem neuroendokrinspezifischen protein änhelt, und dafür kodierende cdns
EP2333064A1 (en) * 1998-11-06 2011-06-15 University of Zürich Nucleotide and protein sequences of Nogo genes and methods based thereon
AU768230B2 (en) 1998-12-22 2003-12-04 Genentech Inc. Methods and compositions for inhibiting neoplastic cell growth
CA2362427A1 (en) 1999-03-08 2000-09-14 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
CA2383592A1 (en) 1999-03-31 2000-10-05 Curagen Corporation 2384891 acids including open reading frames encoding polypeptides; orfx
AU3632600A (en) 1999-05-14 2000-12-05 Genentech Inc. Compositions and methods for the treatment of immune related diseases
EP1268506A4 (en) 1999-07-30 2004-07-28 Millennium Pharm Inc SECRET PROTEINS AND THEIR USE
WO2001042286A2 (en) 1999-12-08 2001-06-14 Millennium Pharmaceuticals, Inc. Human leucine rich repeat-containing polypeptide and uses therefor
US7119165B2 (en) 2000-01-12 2006-10-10 Yale University Nogo receptor-mediated blockade of axonal growth
IL150566A0 (en) * 2000-01-12 2003-02-12 Univ Yale Nucleic acids and polypeptides and nogo-receptor proteins
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
US6695956B2 (en) 2000-04-18 2004-02-24 Teijin Limited Oxygen concentrating apparatus
PT1325130E (pt) * 2000-10-06 2010-05-31 Biogen Idec Inc Homólogos do receptor de nogo
US20040259092A1 (en) 2001-08-27 2004-12-23 Carmen Barske Nogo receptor homologues and their use
JP2005519584A (ja) 2001-10-22 2005-07-07 ノバルティス アクチエンゲゼルシャフト Ｎｏｇｏレセプターホモログおよびそれらの使用
WO2004014311A2 (en) 2002-08-10 2004-02-19 Yale University Nogo receptor antagonists

Also Published As

Publication number Publication date
US20070104713A1 (en) 2007-05-10
US20110129477A1 (en) 2011-06-02
WO2002029059A2 (en) 2002-04-11
JP2009100767A (ja) 2009-05-14
NZ525422A (en) 2006-09-29
PT1325130E (pt) 2010-05-31
DK1325130T3 (da) 2010-05-25
AU2002211539B2 (en) 2007-01-25
ATE458815T1 (de) 2010-03-15
US20050048520A1 (en) 2005-03-03
WO2002029059A9 (en) 2003-05-15
WO2002029059A3 (en) 2003-01-23
US7173118B2 (en) 2007-02-06
CA2424834A1 (en) 2002-04-11
AU1153902A (en) 2002-04-15
US20090175850A1 (en) 2009-07-09
EP1325130B1 (en) 2010-02-24
JP2004528809A (ja) 2004-09-24
ES2341608T3 (es) 2010-06-23
US20030124704A1 (en) 2003-07-03
US7456255B2 (en) 2008-11-25
EP1325130A2 (en) 2003-07-09
JP4465148B2 (ja) 2010-05-19

Similar Documents

Publication Publication Date Title
DE60141409D1 (de) Homologe des nogo rezeptors
MXPA02006885A (es) Bloqueo del crecimiento axonal mediado por receptor de nogo.
WO2003031462A3 (en) Nogo receptor-mediated blockade of axonal growth
DE60028970D1 (de) An her2 bindende peptidverbindungen
CY1111912T1 (el) Μεθοδος αναστολης της δραστηριοτητας των οστεοκλαστων
DK1434791T3 (da) Specifikke bindingsmidler til human angiopoietin-2
EA200301158A1 (ru) Антитела, блокирующие cripto, и их применения
ATE376559T1 (de) Methoden der verhinderung und behandlung der alzheimer'schen krankheit
WO2002044320A3 (en) Human elongase genes and uses thereof
WO2004019893A3 (en) Modulators of angiogenesis
HUP0402327A2 (hu) Inzulinszerű növekedési faktort kötő 5-ös fehérje expressziójának antiszensz módosítása
ATE247130T1 (de) Inhibitoren für den urokinaserezeptor
WO2010065536A3 (en) Recombinant bone marrow stromal antigen-2 in the treatment of autoimmune diseases
DK0811068T3 (da) Humane DNase I varianter
ATE407944T1 (de) Mit trp-proteinen verwandtes protein mtr1 und dieses codierende dna-sequenz
AU9683401A (en) Flea peritrophin nucleic acid molecules, proteins and uses thereof
DE50000562D1 (de) Mittel zur behandlung von pigmentierungsstörungen
WO2002000834A3 (fr) Nouveau polypeptide, proteine phosphatase humaine 9.68, et polynucleotide codant ce polypeptide
WO2002062996A1 (en) Novel physiologically active peptide and use thereof
WO2002046380A3 (en) Protein kinase
TW200635953A (en) Specific binding agents of human angiopoietin-2

Legal Events

Date Code Title Description
8364 No opposition during term of opposition